Results 131 to 140 of about 4,418 (175)
Some of the next articles are maybe not open access.
Pharmacokinetics of oral vitamin D3 and calcifediol
Bone, 2014Long-term pharmacokinetics after supplementation with vitamin D3 or calcifediol (the 25-hydroxyvitamin D3 metabolite) is not well studied. Additionally, it is unclear whether bolus doses of vitamin D3 or calcifediol lead to 25(OH)D3 plasma concentrations considered desirable for fracture prevention (30 ng/mL).
Alexander Jetter +7 more
openaire +2 more sources
Vitamin D supplementation: cholecalciferol, calcifediol, and calcitriol
European Journal of Clinical Nutrition, 2020The specific compound that is meant for use in the context of vitamin D supplementation is often ambiguous. The term "supplementation" has been used in the context of cholecalciferol, ergocalciferol, calcidiol, and calcitriol. In nature, by far the major form of vitamin D that nurtures the body is cholecalciferol.
openaire +2 more sources
Cholecalciferol and calcifediol for vitamin D supplementation
Osteoporosis International, 2019Q1
openaire +2 more sources
Calcifediol improves lipid profile in osteopenicatorvastatin‐treated postmenopausal women
European Journal of Clinical Investigation, 2015AbstractBackgroundLow vitamin D serum levels have been associated with unfavourable lipid profile and poorer response to atorvastatin. Aims of this study were to test the effects of 25‐hydroxyvitamin D3 (calcifediol) compared to parental vitamin D3 (cholecalciferol) supplementation on modifications of plasma 25(OH)D levels and lipid profile.Materials ...
CATALANO, ANTONINO +4 more
openaire +3 more sources
Calcifediol in Chronic Renal Insufficiency-Reply
JAMA: The Journal of the American Medical Association, 1976We appreciate the comments of Drs Coburn and Norman, particularly as regards the hypercalcemic potential of any analogue of vitamin D, illustrating the great care necessitated in using these compounds. We also concur that the superiority (if any) of one natural or synthetic analogue is yet to be proved, although there are little data in the report from
openaire +1 more source
Archives of Internal Medicine, 1978
The synthetic analogues of vitamin D, either ergocalciferol or dihydrotachysterol, have been the mainstay of treatment for hypoparathyroidism (HP) for nearly 40 years. 1 The results have usually been unsatisfactory 2,3 owing mainly to serious defects in the available pharmaceutical preparations.
openaire +2 more sources
The synthetic analogues of vitamin D, either ergocalciferol or dihydrotachysterol, have been the mainstay of treatment for hypoparathyroidism (HP) for nearly 40 years. 1 The results have usually been unsatisfactory 2,3 owing mainly to serious defects in the available pharmaceutical preparations.
openaire +2 more sources
Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study
Nutrients, 2021Juan Francisco Alcalá Díaz +2 more
exaly